Notably, blocking PD-1 and CTLA-4 ex vivo with monoclonal antibodies, and inhibiting PD-1 in vivo with pembrolizumab, has been shown to restore mutCALR-specific T-cell immunity in some mutCALR MPN patients. The gene discussed is CTLA4; the disease is myeloproliferative neoplasm.